Ben Izar's lab is a pioneer in combining single cell techniques, genome-editing, and systems biology to explore the cancer field’s most pressing problems.
Including BRCA1 testing with prenatal carrier screening could identify people at risk of breast, ovarian, and pancreatic cancer at a time when cancer screening could save their lives.
A study from Columbia researchers suggests that changing a single letter in the DNA code of selected genes in T cells may supercharge cell therapies against cancer.
In a phase 1 study, eight out of 12 patients with relapsed and/or refractory blood cancers responded to a combination of two common chemotherapy drugs.
Dr. Drake studies the body’s immunological response to radiation therapy and how immunotherapy and radiation therapy can be used in concert to treat cancer.
Adding a new drug called olaratumab to traditional chemotherapy increased survival in sarcoma patients, researchers at Columbia University Medical Center have found.
The three-dimensional structure could help researchers develop novel therapies and diagnostic tools for diseases that are caused by a malfunction in calcium adsorption.
According to a new report published in JAMA Oncology, women with BRCA1 mutations have a higher risk of developing an aggressive type of uterine cancer.
$4 million grant gives Columbia, Weill Cornell Medicine, NewYork-Presbyterian, and NYC Health + Hospitals key role in precision medicine cohort program.